SCHEDULE: AIGH Capital Management Reports 5.9% Stake in Kyverna Therapeutics

AIGH Capital Management LLC and affiliated entities have reported beneficial ownership of 5.9% of Kyverna Therapeutics, Inc.'s common stock as of September 30, 2026.

Summary

• AIGH Capital Management LLC, AIGH Investment Partners L.L.C., and Orin Hirschman have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 3,650,000 shares of Kyverna Therapeutics, Inc. common stock.
• This ownership represents 5.9% of the class of securities.
• The reporting persons are identified as an investment adviser (AIGH Capital Management LLC) and an investment company (AIGH Investment Partners L.L.C.).
• The date of the event requiring this filing was September 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Significant stake reported by AIGH Capital Management, indicating investor confidence or strategic interest in Kyverna Therapeutics.

Negatives

• No new financial or operational information is provided, limiting insight into the company's performance.

Risks

• The filing does not disclose the specific purpose of the investment, which could range from passive investment to active influence.
• Potential for future changes in beneficial ownership, which could impact stock price volatility.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future company performance.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, particularly in the biotechnology sector where Kyverna Therapeutics operates. This filing indicates a notable position by AIGH Capital Management.

Stakeholder Impact

• Shareholders: May observe increased trading volume or price fluctuations due to the reporting of a significant stake by an institutional investor.
• Management: May need to engage with AIGH Capital Management regarding their investment strategy and intentions.

Next Steps

• Continued monitoring of Kyverna Therapeutics' performance and any subsequent filings by AIGH Capital Management or other significant shareholders.

Key Dates

Keywords

Kyverna Therapeutics, Schedule 13G, Beneficial Ownership, AIGH Capital Management, Investment Management, Securities Exchange Act